Interested In Trying a New Migraine Abortive? The Trials Are Open!
You may remember that I interviewed Dr. Tony Ho about a new Migraine abortive medication at last year's American Headache Society conference. If you didn't read about it or would like to reread it, see New Migraine Abortive Shows Promise without Vasoconstriction.
The medication is still know by a number, MK0974, and is being developed by Merck. It is now in Phase III clinical trials, the last phase before Merck seeks FDA approval of the medication. In Phase III trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Are you interested in being in this trial? Here are the eligibility requirements and criteria:
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
- Patient has had a history of migraines within the past year.
- Patient has had 1 to 8 moderate or severe migraine attacks per month in the past 2 months that lasted between 4 - 72 if untreated.
- Patients must use acceptable contraception throughout the study.
- Patient is able to complete the study questionnaire(s) and paper diary.
- Limit consumption of grapefruit juice to no more than one 8 ounce glass a day.
- Patient is pregnant or breast-feeding or is expecting to become pregnant during the study.
- Patient has difficulty distinguishing his/her migraine attacks from tension or interval headaches.
- Patient has a history of mostly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours.
- Patient has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days a month in the past 3 months.
- Patient was greater than 50 years old at the age of migraine onset. (First Migraine)
- Patient has previously taken MK0974.
This study is being conducted in 28 locations in the United States, Australia, Denmark, Germany, Netherlands, Norway, and United Kingdom. You can find a complete listing of the locations HERE.
For more information about this study please click the link above, or you may call 1-888-577-8839. Please refer to this study by its ClinicalTrials.gov identifier: NCT00483704.